Selenium compounds as promising antiviral agents

The past two decades of this century have faced half a dozen pandemics caused by different kinds of viruses, affecting millions of people globally. Among them three zoonotic viruses of the beta-coronavirus family, namely SARS-CoV-1, MERS-CoV and SARS-CoV-2, have emerged in a span of 17 years. Prevention of viral infection using vaccines is the foremost strategy to combat viral infection, but development of a vaccine for a virus remains a challenging task due to high genetic diversity and high mutation rates. Treatment of viral disease at different stages by antiviral drugs is another strategy. Several antiviral agents, primarily aiming to disrupt the viral life cycle, have been developed. Extensive research in different labs across the globe has shown that selenium deficiency has been associated with pathogenicity of several viruses like influenza viruses, HIV, HBV, HSV-1, etc. While dietary selenium supplementation has been practiced clinically, researchers are now focusing on developing new synthetic organoselenium compounds as novel antiviral agents. In this essay we have covered different classes of selenium compounds, viz. N-heterocyclic selenium derivatives, ebselen and its derivatives, organoselenium compounds, and selenium nanoparticles, which have been evaluated for effective management of viral infections. Selenium deficiency increases pathogenicity of RNA viruses. While dietary selenium supplementation has been practiced clinically, synthetic selenium compounds are under evaluation for their antiviral activity, important classes are discussed in this essay.